Universe Pharmaceuticals INC
UPC
$5.94
-$1.15-16.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.04% | -15.87% | -22.44% | -25.32% | -27.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.04% | -15.87% | -22.44% | -25.32% | -27.81% |
| Cost of Revenue | -16.11% | -24.88% | -31.82% | -30.84% | -29.96% |
| Gross Profit | 10.43% | 7.05% | 3.77% | -10.71% | -22.35% |
| SG&A Expenses | -30.89% | -26.91% | -22.81% | -8.24% | 6.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -93.94% | -95.58% |
| Total Operating Expenses | -28.92% | -31.11% | -33.08% | -23.50% | -14.37% |
| Operating Income | 75.72% | 69.90% | 63.64% | 16.96% | -46.98% |
| Income Before Tax | 79.94% | 80.31% | 80.50% | 62.76% | 43.13% |
| Income Tax Expenses | -- | -- | -- | -102.29% | -103.00% |
| Earnings from Continuing Operations | 79.82% | 80.68% | 81.11% | 65.38% | 49.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.82% | 80.68% | 81.11% | 65.38% | 49.27% |
| EBIT | 75.72% | 69.90% | 63.64% | 16.96% | -46.98% |
| EBITDA | 80.12% | 74.36% | 68.16% | 18.55% | -51.24% |
| EPS Basic | 98.85% | 97.69% | 97.14% | -5.48% | -- |
| Normalized Basic EPS | 98.86% | 97.71% | 97.17% | -5.43% | -- |
| EPS Diluted | 98.85% | 97.69% | 97.14% | -5.48% | -- |
| Normalized Diluted EPS | 98.86% | 97.71% | 97.17% | -5.43% | -- |
| Average Basic Shares Outstanding | 136.14% | 235.95% | 4,576.38% | 6,766.06% | -- |
| Average Diluted Shares Outstanding | 136.14% | 235.95% | 4,576.38% | 6,766.06% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |